Q3 FY2022 · Press release
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody · 3 pages
Read Zymeworks Inc.'s results firsthand
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional